What does BioLineRx do?
BioLineRx Ltd. is an Israel-based biopharmaceutical company listed on Nasdaq and the Tel Aviv Stock Exchange under BLRX. It operates as a lean clinical-development and licensing business. Its first approved therapy is APHEXDA, or motixafortide, while GLIX1 is the lead internally directed program for glioblastoma and other solid tumors.
The business has three practical value centers. APHEXDA supplies royalty and milestone optionality through commercial partners. BioLineRx retains non-Asian solid-tumor rights to motixafortide, including metastatic pancreatic ductal adenocarcinoma, where an investigator-led Phase 2b study is ongoing. GLIX1 provides a new proprietary growth platform through Tetragon Biosciences, the jointly governed development vehicle created with Hemispherian. The official BioLineRx pipeline shows how the company has shifted from a single-product launch story to a partner-funded royalty stream plus oncology development portfolio.
How does BioLineRx make money?
BioLineRx’s current revenue model is licensing-led. It no longer books APHEXDA product sales from its own U.S. field organization; instead, it receives royalties on partner sales and may collect development, regulatory, and commercial milestones. This materially reduces selling infrastructure and working-capital needs, but it also transfers launch execution, pricing access, reimbursement, and market penetration to partners.
What are the main revenue streams?
| Agreement | Upfront economics | Potential milestones | Ongoing economics |
|---|---|---|---|
| Ayrmid, signed November 20, 2024 | $10.0M upfront | Up to $87.0M in commercial and sales milestones | 18%-23% royalties on net sales plus cost-plus manufacturing supply |
| Gloria / Hong Seng, closed October 2023 | $15.0M upfront plus a separate $14.6M strategic equity investment | Up to $49.0M development and regulatory milestones and up to $197.0M sales milestones | Tiered double-digit royalties in the licensed Asian territory |
The Ayrmid transaction converted a costly direct-commercialization model into a high-percentage royalty model. The separate Gloria agreement provides geographic diversification and additional clinical-development leverage in Asia.
Why is the model economically unusual?
What did BioLineRx’s first quarter of 2026 show?
Q1 2026 showed rising APHEXDA royalties, higher GLIX1 spending, and continued cash burn. The latest official Q1 2026 results are more informative than revenue alone because the company is still financing clinical work rather than operating as a mature royalty company.
Which financial lines changed most?
| Metric | Q1 2026 | Year-over-year signal | Interpretation |
|---|---|---|---|
| Royalty revenue | $0.477M | Up about 87% | Higher APHEXDA sales increased recurring revenue. |
| Gross profit | $0.382M | Higher | Royalty economics remained attractive after sublicense costs. |
| R&D expense | $2.528M | Up 55.8% | The increase primarily reflected the new GLIX1 program. |
| G&A expense | $0.858M | Down 13.3% | Administrative spending continued to decline. |
| Operating loss | $3.004M | Wider | Higher GLIX1 investment more than offset the royalty improvement. |
| Net loss | $2.588M | Prior-year result was distorted by warrant revaluation | Non-cash warrant movements make operating cash flow more informative than net income. |
| Operating cash flow | $2.280M used | Improved modestly | Cash burn was lower despite higher reported R&D expense. |
What does the quarter imply about cash runway?
At March 31, 2026, $2.504M of cash plus $14.849M of deposits totaled about $17.4M. Management previously guided the December 31, 2025 balance of $20.9M into the first half of 2027. Q1 operating cash use was $2.280M, but runway still depends on clinical spending, debt service, partner receipts, and financing.
Which strategic turning points created today’s BioLineRx?
BioLineRx’s history is best understood through changes in business architecture: who funds commercialization, who bears clinical risk, and which economics remain with the company.
-
2003BioLineRx was founded by Israeli life-sciences institutions, establishing an asset-scouting and in-licensing model rather than a single laboratory-origin platform.
-
2007-2011The company listed ordinary shares on the TASE in 2007 and ADSs on Nasdaq in 2011, creating access to both Israeli and U.S. capital markets.
-
September 2023The FDA approved APHEXDA. The FDA approval record marked BioLineRx’s first successful transition from development asset to marketed therapy.
-
October 2023The Gloria transaction licensed motixafortide across most of Asia and supplied upfront cash, milestone potential, royalties, and a strategic shareholder relationship.
-
November 2024The Ayrmid agreement transferred non-Asian APHEXDA commercialization and most non-solid-tumor development rights, allowing BioLineRx to close its U.S. commercial organization and reduce operating costs.
-
September 2025BioLineRx and Hemispherian formed the Tetragon structure for GLIX1, restoring an internally directed oncology growth program while sharing economics and governance.
-
Q1-Q3 2026GLIX1 entered Phase 1/2a clinical testing, and new ovarian-cancer combination data expanded the program’s strategic scope beyond glioblastoma.
How did the 2024 transformation change the financial model?
What gives BioLineRx a competitive advantage?
BioLineRx lacks large-pharma scale. Its potential advantage is procedural: source external assets, advance them through clinical and regulatory development, structure partnerships, and preserve selected downstream economics. APHEXDA’s approval validates that process, while the company’s small scale makes each program disproportionately important.
Where is the moat most credible?
Which competitors pressure the business?
| Market or program | Competitive reference | BioLineRx differentiator | Main pressure |
|---|---|---|---|
| Stem-cell mobilization | Mozobil / plerixafor and multiple lower-priced generics | GENESIS showed strong single-dose mobilization when combined with G-CSF. | Generic price competition and transplant-center adoption. |
| Glioblastoma | Temozolomide, Optune, bevacizumab, GLIADEL, and multiple investigational agents | GLIX1 targets a distinct TET2/DNA-repair mechanism and is brain penetrating. | Very high clinical-failure rates and strong competition for patients and capital. |
| Metastatic pancreatic cancer | FOLFIRINOX, gemcitabine/Abraxane, NALIRIFOX, and targeted options for small subgroups | Motixafortide is intended to alter the tumor microenvironment and improve immunotherapy activity. | Interim efficacy must translate from early data into randomized progression-free-survival benefit. |
GLIX1, APHEXDA, and pancreatic cancer define the clinical portfolio
Why is GLIX1 the lead growth asset?
GLIX1 is a first-in-class, orally administered, brain-penetrating small molecule designed to activate the TET2 pathway and overwhelm cancer-cell DNA-repair capacity. The open-label Phase 1/2a trial began in the first quarter of 2026. Its dose-escalation part is expected to recruit up to 30 patients with recurrent or progressive glioblastoma and other high-grade gliomas, with safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy used to select a recommended dose.
The July 8, 2026 Form 6-K update reported preclinical synergy between low-dose GLIX1 and olaparib in an HR-proficient ovarian-cancer model. On July 20, BioLineRx also announced that related data had been accepted for an ESMO 2026 e-poster. These results are not clinical proof, but they support adding ovarian cancer and PARP-inhibitor combinations to the planned expansion strategy.
What still matters for motixafortide?
APHEXDA is supported by the Phase 3 GENESIS trial and the September 2023 FDA-approval announcement. The remaining question is whether Ayrmid can expand adoption against generic plerixafor while preserving net pricing. In pancreatic cancer, early single-arm activity must survive randomized testing and a futility check.
How financially strong is BioLineRx?
BioLineRx has a smaller cost base and lower debt than before the 2024 restructuring, but it is not financially self-sustaining. Royalty revenue remains far below R&D and corporate expense, and the FY2025 audit included a going-concern explanatory paragraph. Financial strength therefore means liquidity relative to burn, contractual milestone potential, and financing flexibility rather than conventional profitability.
What does the annual report say?
| Financial measure | FY2025 | Change from FY2024 | Interpretation |
|---|---|---|---|
| Revenue | $1.180M | Lower after license upfront and direct sales ended | FY2025 revenue was royalty based and should not be compared mechanically with the transaction-heavy prior year. |
| Gross profit | $0.950M | Lower with the new revenue base | Gross margin remained about 80.5%, consistent with royalties net of sublicense fees. |
| R&D expense | $8.093M | Lower | Motixafortide costs fell after out-licensing, partly offset by GLIX1 initiation. |
| Sales and marketing | $0.000M | Eliminated | The U.S. commercial shutdown removed the former largest expense category. |
| G&A expense | $3.144M | Down 50.3% | Lower headcount and corporate costs drove the decline. |
| Operating loss | $10.287M | Narrower | The cost reset materially reduced the operating deficit. |
| Net loss | $2.026M | Narrower | Warrant fair-value income reduced the reported loss and is not operating cash generation. |
| Operating cash flow | $8.1M used | Substantially improved | Cash burn reduction is the clearest benefit of the 2024 transaction. |
These figures come from the company’s 2025 Form 20-F, filed March 23, 2026.
How much balance-sheet flexibility remains?
| Balance-sheet item | Latest disclosed amount | Period | Analytical meaning |
|---|---|---|---|
| Cash and equivalents | $2.504M | March 31, 2026 | Most liquidity is held in short-term deposits rather than cash. |
| Short-term deposits | $14.849M | March 31, 2026 | Primary source of near-term liquidity and interest income. |
| Total assets | $38.797M | March 31, 2026 | The business is not capital intensive; liquidity and intangible assets dominate. |
| Total equity | $20.835M | March 31, 2026 | The quarterly loss reduced equity; non-controlling interest reflects Tetragon. |
| Current plus long-term loan | $8.939M | December 31, 2025 | Scheduled debt service through December 2027 competes with clinical spending. |
Who owns BioLineRx stock, and how is it governed?
BioLineRx has one class of ordinary shares, while U.S. investors generally trade ADSs. Since January 30, 2025, each ADS represents 600 ordinary shares. Ownership is dispersed, although Hong Seng Technology remains strategically important through the Asian motixafortide relationship.
What does the disclosed ownership table show?
| Holder or group | Ordinary shares beneficially owned | Percent of class | Why it matters |
|---|---|---|---|
| Hong Seng Technology Limited | 102,437,055 | 3.9% | Strategic holder linked to the Gloria license relationship and Asian development economics. |
| All directors and executive officers as a group | 51,613,800 | 1.94% | Management has economic exposure, but does not exercise controlling voting power. |
| Chief Executive Officer Philip Serlin | 18,226,800 | Less than 1% | Most disclosed beneficial ownership includes exercisable options or awards rather than a large founder block. |
| Ordinary shares outstanding | 2,610,814,390 | 100% | Large ordinary-share count reflects the 600-to-1 ADS representation rather than a similarly large ADS count. |
What governance signals should researchers note?
What opportunities and risks could change the story?
BioLineRx combines a small royalty stream with high-variance clinical and financing outcomes. Successful oncology data or stronger APHEXDA adoption could change the economics; failed trials or financing pressure could narrow strategic flexibility.
Where does the company sit strategically?
Which opportunities deserve attention?
What are the most material risks?
| Risk | Financial or strategic transmission | What to monitor |
|---|---|---|
| Clinical failure | Could impair GLIX1 or motixafortide value and force pipeline reprioritization. | Dose-limiting toxicities, pharmacodynamic evidence, PFS events, and enrollment pace. |
| Partner dependence | Royalties and milestones depend on Ayrmid and Gloria execution, timing, reimbursement, and commercial resources. | Quarterly APHEXDA sales, Asian study progress, and milestone disclosures. |
| Generic plerixafor competition | Lower-priced alternatives may constrain APHEXDA adoption, discounts, and royalty growth. | Center penetration, repeat ordering, net pricing, and payer access. |
| Financing and dilution | A runway shortfall could require new ADSs, warrants, debt, or asset rights to be issued. | Quarterly cash burn, runway guidance, warrant exercises, and financing terms. |
| Intellectual property | Challenges to patents or upstream licenses could reduce exclusivity or terminate downstream economics. | Patent estate updates, license disputes, generic entry, and royalty-term changes. |
| Israel operating exposure | Security conditions may disrupt employees, vendors, laboratories, or capital-market access. | Business continuity, staffing, clinical logistics, and cash-location disclosures. |
Why does BioLineRx matter for valuation?
A single-stage DCF is a poor fit because revenue is small, milestones are discrete, and clinical outcomes are binary. A better framework separates approved-product royalties, milestones, pipeline assets, and corporate burn, then probability weights each component on a fully diluted per-ADS basis.
Which drivers belong in a BioLineRx model?
Which KPIs should a researcher update each quarter?
What is the key takeaway from BioLineRx analysis?
BioLineRx is no longer best described as an APHEXDA launch company. It is a small, partner-dependent biotech with one approved asset generating royalties, one retained motixafortide solid-tumor option, and one early-stage oncology platform intended to create the next cycle of value. The 2024 licensing transaction dramatically improved cost structure and cash efficiency, but it also made partner execution central to the revenue story.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.